Immunomic Therapeutics’ CEO to Present at the 5th International Virtual Conference on Cancer Research & Development 2020

October 20, 2020 Off By BusinessWire

ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI) announced today that it will be presenting at the 5th International Virtual Conference on Cancer Research & Development. On Monday, October 26, 2020, Chief Executive Officer at ITI, Dr. Bill Hearl, will be presenting a talk titled, “UNITE Platform, A Direct Antigen Presentation Approach in Oncology.” Dr. Hearl will discuss ITI’s investigational platform technology, the company’s lead program and its preliminary data, as well as the company’s future focus.

Panel details are as follows:

Title: UNITE Platform, A Direct Antigen Presentation Approach in Oncology

Panel Category: Cancer Immunology

Panel Date and Time: Monday, October 26, 2020 1:10-1:35 PM ET

Location: Cancer R&D Virtual Symposium

About UNITE

ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein 1, an endogenous protein in humans, for immune processing. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach puts UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in a Phase II clinical trial as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. (Read more…) Preclinical data is currently being developed to explore whether LAMP1 nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that generate broad immune responses. ITI’s UNITE platform could potentially have broad therapeutic applications in oncology, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics and ITI has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.

Contacts

Company Contact:
Sia Anagnostou

[email protected]
717-327-1822

Media Contact:
Amy Conrad

Juniper Point

[email protected]
858-366-3243